

Date: July 9, 2001




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Pennica et al.
Appl. No. : 09/759,056
Filed : January 11, 2001
For : NOVEL STRA6
POLYPEPTIDES
Examiner : Unknown
Group Art Unit : 1645

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in
an envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231, on

July 9, 2001

(Date)


Ginger R. Dreger, Reg. No. 33,055


TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231
ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with 229 references.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record

GENENT.2827A2



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pennica et al.) Group Art Unit 1645
App. No. : 09/795,056)
Filed : January 11, 2001)
For : NOVEL STRA6)
POLYPEPTIDES)
Examiner : Unknown)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 9, 2001

By: Ginger R. Dreger
Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO
GENENT.2827A2APPLICATION NO
09/759,056INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Pennica et alFILING DATE
January 11, 2001GROUP
1645

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	3,773,919	11 20 73	Boswell et al.			
	2.	4,179,337	12 18 79	Davis et al.			
	3.	4,275,149	6 23 81	Litman et al.			
	4.	4,399,216	8 16 83	Axel et al.			
	5.	4,485,045	11 27 84	Regen			
	6.	4,496,689	1 29 85	Mitra			
	7.	4,544,545	10 1 85	Ryan et al.			
	8.	4,640,835	2 3 87	Shimizu et al.			
	9.	4,657,760	4 14 87	Kung et al.			
	10.	4,670,417	6 2 87	Iwasaki et al.			
	11.	4,676,980	6 30 87	Segal et al.			
	12.	4,736,866	4 12 88	Leder et al.			
	13.	4,791,192	12 13 88	Nakagawa et al.			
	14.	4,816,567	3 28 89	Cabilly et al.			
	15.	4,870,009	9 26 89	Evans et al.			
	16.	4,873,191	10 10 89	Wagner et al.			
	17.	4,943,529	7 24 90	Van Den Berg et al.			
	18.	4,975,278	12 4 90	Senter et al.			
	19.	5,010,182	4 23 91	Brake et al.			
	20.	5,013,556	5 7 91	Woodle et al.			
	21.	5,122,469	6 16 92	Mather et al.			
	22.	5,206,344	4 27 93	Katre et al.			
	23.	5,225,212	7 6 93	Martin et al.			
	24.	5,428,130	6 27 95	Capon et al.			
	25.	5,545,806	8 13 96	Lonberg et al.			
	26.	5,545,807	8 13 96	Surani et al.			

*EXAMINER: INITIAL IF CITATION IS CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 100. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GENENT 2827A2APPLICATION NO.
09/759,056INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Pennica et alFILING DATE
January 11, 2001GROUP
1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	3,773,919	11 20 73	Boswell et al.			
	2.	4,179,337	12 18 79	Davis et al.			
	3.	4,275,149	6 23 81	Litman et al.			
	4.	4,399,216	8 16 83	Axel et al.			
	5.	4,485,045	11 27 84	Regen			
	6.	4,496,689	1 20 85	Mitra			
	7.	4,544,545	10 1 85	Ryan et al.			
	8.	4,640,835	2 4 87	Shimizu et al.			
	9.	4,657,760	4 14 87	Kung et al.			
	10.	4,670,417	6 2 87	Iwasaki et al.			
	11.	4,676,980	6 30 87	Segal et al.			
	12.	4,736,866	4 12 88	Leder et al.			
	13.	4,791,192	12 13 88	Nakagawa et al.			
	14.	4,816,567	3 28 89	Cabilly et al.			
	15.	4,870,009	9 26 89	Evans et al.			
	16.	4,873,191	10 10 89	Wagner et al.			
	17.	4,943,529	7 24 90	Van Den Berg et al.			
	18.	4,975,278	12 4 90	Senter et al.			
	19.	5,010,182	4 23 91	Brake et al.			
	20.	5,013,556	5 7 91	Woodle et al.			
	21.	5,122,469	6 16 92	Mather et al.			
	22.	5,206,344	4 27 93	Hatre et al.			
	23.	5,225,212	7 6 93	Martin et al.			
	24.	5,428,130	6 27 95	Capon et al.			
	25.	5,545,806	8 13 96	Lonberg et al.			
	26.	5,545,807	8 13 96	Surani et al.			

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GENENT 2827A2APPLICATION NO.
09/759,056INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Pennica et alFILING DATE
January 11, 2001GROUP
1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	27	5,569,825	10/29/96	Lonberg et al.			
	28	5,625,126	4/29/97	Lonberg et al.			
	29	5,633,425	5/27/97	Lonberg et al.			
	30	5,654,010	8/5/97	Johnson et al.			
	31	5,661,016	8/26/97	Lonberg et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	32	EP 03089	05/30/90	EP				
	33	EP 117,058	08/29/84	EP				
	34	EP 117,060	08/29/84	EP				
	35	EP 139,383	05/02/85	EP				
	36	EP 307,247	03/15/88	EP				
	37	EP 36,776	09/30/81	EP				
	38	EP 362,179	04/04/90	EP				
	39	EP 394,538	10/31/90	EP				
	40	EP 404,097	12/27/90	EP				
	41	EP 616,812	09/28/94	EP				
	42	EP 073,657	03/09/83	EP				
	43	WO 81/01145	4/20/81	PCT				
	44	WO 87/05330	9/11/87	PCT				
	45	WO 84/03564	9/13/84	PCT				
	46	WO 88/07378	10/6/88	PCT				
	47	WO 89/05859	6/29/89	PCT				
	48	WO 90/10048	9/7/90	PCT				
	49	WO 90/13641	11/15/90	PCT				
		WO 90/13641						

*EXAMINER: INITIAL CITATION IS CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GENENT 2827A2APPLICATION NO.
09/759,056INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Pennica et alFILING DATE
January 11, 2001GROUP
1645

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	51.	WO 91/00357	1.10.91	PCT				
	52.	WO 91/00360	1.10.91	PCT				
	53.	WO 91/04753	4.18.91	PCT				
	54.	WO 93/11161	6.10.93	PCT				
	55.	WO 93/18186	9.16.93	PCT				
	56.	WO 94/11026	5.26.94	PCT				
	57.	WO 96/07399	3.14.96	PCT				
	58.	WO 96/27011	9.6.96	PCT				
	59.	WO 96/40072	12.19.96	PCT				
	60.	WO 97/03692	2.6.97	PCT				
	61.	WO 97/33551	9.18.97	PCT				


EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	62.	Alitalo and Schwab "Oncogene Amplification in Tumor Cells" <u>Adv. Cancer Res.</u> , 47:235-281 (1986)
	63.	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs" <u>Nucleic Acids Res.</u> 25(17):3389-3402 (1997)
	64.	Anderson et al., "Direct Interactions of Coxsakievirus B3 with Immune Cells in the Splenic Compartment of Mice Susceptible or Resistant to Myocarditis" <u>Science</u> 256, 808-813 (1992)
	65.	Athauda et al., "Entrapment and Inhibition of Human Immunodeficiency Virus Proteinase by a 2-Macroglobulin and Structural Changes in the Inhibitor" <u>J. Biochem.</u> , 113:742-746 (1993)
	66.	Ausubel et al., <u>Current Protocols of Molecular Biology</u> , John Wiley and Sons (1997)
	67.	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185her2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> , 14:737-744 (1996)
	68.	Baselga et al., "HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic implications" <u>Oncology</u> , 11 (3 Suppl 1):43-48 (1997)
	69.	Beach and Nurse, "High-frequency transformation of the fission yeast <i>Schizosaccharomyces pombe</i> " <u>Nature</u> , 290: 140 (1981)
	70.	Beal and Dervan et al., "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation" <u>Science</u> , 251:1360 (1991)
	71.	Bishop, Michael J., "Molecular Themes in Oncogenesis" <u>Cell</u> , 64:235-248 (1991)
	72.	Boerner et al., "Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes" <u>J. Immunol.</u> 147(1):86-95 (1991)

*EXAMINER: INITIAL IF CITATION CONSIDERED; WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GENENT.2827A2APPLICATION NO.
09/759,056INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Pennica et alFILING DATE
January 11, 2001GROUP
1645


OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- | | |
|-----|--|
| 73. | Bolivar et al., "Construction and characterization of new cloning vehicles" <u>Gene</u> , 2:95-113 (1977) |
| 74. | Boring et al., "Cancer Statistics, 1993" <u>CA Cancer J. Clin.</u> , 43:7 (1993) |
| 75. | Bouillet et al., "Efficient Cloning of cDNA of Retinoic Acid-Responsive Genes in P19 Embryonal Carcinoma Cells and Characterization of a Novel Mouse Gene, Stra1 (Mouse LERK-2/Eplg2) <u>Dev. Biol.</u> 170:420-433 (1995) |
| 76. | Bouillet et al., "Developmental expression pattern of Stra6, a retinoic acid-responsive gene encoding a new type of membrane protein" <u>Mechanisms of Development</u> 63, 173-186 (1997) |
| 77. | Boven and Winograd, eds., <u>The Nude Mouse in Oncology Research</u> , CRC Press, Inc., 1991 |
| 78. | Bradley, Allan, "Production and analysis of Chimaeric mice" in <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed. (IRL, Oxford, 1987), 5:113-152 |
| 79. | Braxton and Wells, "Incorporation of Stabilizing Ca2+-Binding Loop into Subtilisin BPN" <u>Biochemistry</u> , 31:7796-7801 (1992) |
| 80. | Brennan et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments" <u>Science</u> 229:81 (1985) |
| 81. | C. Anthony, <u>The Biochemistry of Methylophilic</u> , 269-295 (1982) |
| 82. | Caron et al., "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies" <u>J. Exp. Med.</u> , 176: 1191-1195 (1992) |
| 83. | Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> , 13:4331 (1986) |
| 84. | Case et al., "Efficient Transformation of Neurospora crassa by Utilizing Hybrid Plasmid DNA" <u>Proc. Natl. Acad. Sci. USA</u> , 76:5259-5263 (1979) |
| 85. | Chang et al., "Phenotype expression in E. coli of a DNA sequence coding for mouse dihydrofolate reductase" <u>Nature</u> , 275:615 (1978) |
| 86. | Chazaud et al., "Restricted Expression of a Novel Retinoic Acid Responsive Gene During Limb Bud Dorsal-Ventral Patterning and Endochondral Ossification" <u>Dev. Genet.</u> 19: 66-73 (1996) |
| 87. | Chevray and Nathans, "Portein interaction cloning in yeast: Identification of mammalian proteins that react with leucine zipper of Jun" <u>Proc. Natl. Acad. Sci. USA</u> , 89: 5789-5793 (1991) |
| 88. | Chien et al., "The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest" <u>Proc. Natl. Acad. Sci. USA</u> , 88:9578-9582 (1991) |
| 89. | Chothia, Cyrus, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>J. Mol. Biol.</u> , 150:1 (1976) |
| 90. | Cleland, Jeffrey L., "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in <u>Vaccine Design: The Subunit and Adjuvant Approach</u> , Powell and Newman, eds. (Plenum Press: New York, 1995), Chapter 18 pp. 439-462 |
| 91. | Cooney et al. "Site-Specific Oligonucleotide Binding Represses transcription of the Human c-myc Gene in Vitro", <u>Science</u> , 241: 456-459 (1988) |
| 92. | Creighton, <u>Proteins: Structure and Molecular Properties</u> , W.H. Freeman & Co., San Francisco, (1983) |
| 93. | Cunningham and Wells, "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis" <u>Science</u> , 244: 1081-1085 (1989) |
| 94. | David and Reisfeld, "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> , 13:1011-1014 (1974) |

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GENENT.2827A2APPLICATION NO.
09/759,056INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Pennica et alFILING DATE
January 11, 2001GROUP
1645

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- | | |
|------|--|
| 95. | deBoer et al., "The tac promoter: A functional hybrid derived from the trp and lac promoters" <u>Proc. Natl. Acad. Sci. USA</u> , 80:21-25 (1983) |
| 96. | DeLeo et al., "Cell Surface Antigens of Chemically Induced Sarcomas of the Mouse" <u>J. Exp. Med.</u> , 146:720-730 (1977) |
| 97. | Deutscher, Murray P. (Ed.), <u>Methods in Enzymology</u> , 182 (1990) |
| 98. | Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" <u>PNAS USA</u> , 83:9129-9133 (1986) |
| 99. | Easwaran et al., "Cross-regulation of -catenin-LEF/TCF and retinoid signaling pathways" <u>Curr. Biol.</u> 9:1415-1418 (1999) |
| 100. | Eberhard et al., "Alterations of Annexin Expression in Pathological Neuronal and Glial Reactions" <u>Am. J. Pathol.</u> 145:640-9 (1994) |
| 101. | Edge et al. "Deglucosylation of Glycoproteins by Trifluoromethanesulfonic Acid", <u>Anal. Biochem.</u> , 118:131-137 (1981) |
| 102. | Epstein et al. "Biological activity of liposome-encapsulated murine interferon is mediated by a cell membrane receptor", <u>Proc. Natl. Acad. Sci. USA</u> , 82: 3688 (1985) |
| 103. | Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular and Cellular Biology</u> , 5:3610-3616 (1985) |
| 104. | Field et al., "Purification of a RAS-Responsive Adenyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Mol. Cell. Biol.</u> , 8:2159-2165 (1988) |
| 105. | Fields and Song, "A novel genetic system to detect protein-protein interactions" <u>Nature</u> , 340:245-246 (1989) |
| 106. | Fishwild et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice" <u>Nature Biotechnology</u> 14, 845-51 (1996) |
| 107. | Fleer et al., "Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by <i>Kluyveromyces</i> Yeasts", <u>Bio/Technology</u> , 9:968-975 (1991) |
| 108. | Fournier and Ozeki, "Structure and Organization of the Transfer Ribonucleic Acid Genes of <i>Escherichia coli</i> K-12", <u>Microbiol. Rev.</u> 49:379-397 (1985) |
| 109. | Freund and Blair "Depression of Natural Killer Activity and Mitogen Responsiveness in Mice Treated With Pristane", <u>J. Immunol.</u> 129:2826-2830 (1982) |
| 110. | Gabizon et al., "Pharmacokinetics and Tissue Distribution of Doxorubicin Encapsulated in Stable Liposomes With Long Circulation Times" <u>J. National Cancer Inst.</u> , 81(19): 1484 (1989) |
| 111. | Gelmini et al., "Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification" <u>Clin. Chem.</u> 43:752 (1997) |
| 112. | Gething et al., "Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene" <u>Nature</u> , 293:620-625 (1981) |
| 113. | Goeddel et al., "Direct expression in <i>Escherichia coli</i> of a DNA sequence coding for human growth hormone" <u>Nature</u> , 281:544 (1979) |
| 114. | Goeddel et al., "Synthesis of human fibroblast by <i>E. coli</i> " <u>Nucleic Acids Res.</u> , 8:4057 (1980) |
| 115. | Lassam et al., "Synthesis of DNA, Late Polypeptides, and Infectious Virus by Host-Range Mutants of Adenovirus 5 in Nonpermissive Cells" <u>Virology</u> , 87:63-467 (1978) |

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT 2827A2	APPLICATION NO. 09/759,056
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Pennica et al	
		FILING DATE January 11, 2001	GROUP 1645

EXAMINER INITIAL TRADEMARK	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
116	Graham et al. "Characteristics of a Human Cell Line Transformed by DNA from human Adenovirus Type 5", <u>J. Gen Virol.</u> , 36:59 (1977)
117	Gray et al. "Fluorescence in Situ Hybridization in Cancer and Radiation Biology", <u>Radiation Res.</u> , 137:275-289 (1994)
118	Gruber et al "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Express in Escherichia coli", <u>J. Immunol.</u> 152:5368 (1994)
119	Hess et al., "Cooperation of Glycolytic Enzymes", <u>J. Adv. Enzyme Reg.</u> , 7:149 (1968)
120	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by Immunological Screening Technique" <u>J. Biol. Chem.</u> , 255:2073 (1980)
121	Hodgson, John, "Data-Directed Drug Design" <u>Bio/Technology</u> , 9: 19-21 (1991)
122	Holland and Holland, "Isolation and Identification of yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase and Phosphoglucerate Kinase" <u>Biochemistry</u> , 17:4900-4907 (1978)
123	Hollinger et al., "Diabodies": Small bivalent and bispecific antibody fragments" <u>Proc. Natl. Acad. Sci. USA</u> , 90:6444-6448 (1993)
124	Hongo et al. "Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor ", <u>Hybridoma</u> 14:253-260 (1995)
125	Hopp et al., "A short polypeptide marker sequence useful for recombinant protein identification and purification" <u>BioTechnology</u> , 6:1204-1210 (1988)
126	Hora et al., "Controlled Release of Interleukin-2 From Biodegradable Microspheres", <u>Bio/Technology</u> , 8:755-758 (1990)
127	Hsiao et al., "High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene" <u>Proc. Natl. Acad. Sci. (USA)</u> , 76:3829 (1979)
128	Hunter, Tony, "Cooperation between Oncogenes" <u>Cell</u> , 64:1129 (1991)
129	Hwang et al. "Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study", <u>Proc. Natl. Acad. Sci. USA</u> , 77: 4030 (1980)
130	Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in cancer" <u>Biochim. Biophys. Acta</u> , 1198:165-184 (1994)
131	Johnson et al., "A month-long effect from a single injection of microencapsulated human growth hormone" <u>Nat. Med.</u> 2:795-799 (1996)
132	Jones et al., <u>Nature</u> , "Replacing the complementary-determining regions in a human antibody with those from a mouse" 321:522-525 (1986)
133	Jones, Elizabeth W., "Proteinase Mutants of <i>Caccharomyces Cerevisiae</i> " <u>Genetics</u> , 85:12 (1977)
134	Karmali et al., "Prostaglandins in breast cancer: Realationship to disease stage and hormone status" <u>Br. J. Cancer</u> , 48:689-696 (1983)
135	Kelly and Hynes, "Transformation of <i>Aspergillus niger</i> by the amdS gene of <i>Aspergillus nidulans</i> " <u>EMBO J.</u> , 4:475-479 (1985)
136	Keown et al., "Methods for Introducing DNA into Mammalian Cells" <u>Methods in Enzymology</u> , 185:527-537 (1990)

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO
GENENT 2827A2APPLICATION NO.
09/759,056INFORMATION DISCLOSURE STATEMENT
BY APPLICANT


(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Pennica et alFILING DATE
January 11, 2001GROUP
1645EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- 137 Kikuchi et al., "The nucleotide sequence of the promoter and the amino-terminal region of alkaline phosphatase structural gene (phoA) of Escherichia coli" Nucleic Acids Res. 9:5671-5678 (1981)
- 138 Kingsman et al. "Replication In Saccharomyces cerevisiae of Plasmid Pbr313 Carrying DNA from the Yeast trp1 Region", Gene, 7:141 (1979)
- 139 Kobayashi et al., "Mutations of the -Catenin Gene in Endometrial Carcinomas" Jpn. J. Cancer Res. 90:55-9 (1999)
- 140 Koesters et al., "Mutational Activation of the -Catening Proto-Oncogene Is a Common Event in the Development of Wilms' Tumors" Cancer Res. 59:3880-2 (1999)
- 141 Komine et al. "Genomic Organizati and Physical Mapping of the Transfer RNA Genes in Escherichia coli K12", J. Mol. Biol. 212:579-598 (1990)
- 142 Korinek et al., "Two members of the Ref family implicated in Wnt/ -Catenin signaling during Embryogenesis in the Mouse" Mol. Cell Biol. 18:1248-56 (1998)
- 143 Kostelny et al. "Formation of a Bispecific Antibody by the Use of Leucine Zippers", J. Immunol. 148(5):1547-1553 (1992)
- 144 Lasko et al., "Targeted oncogene activation by site-specific recombination in transgenic mice" Proc. Natl. Acad. Sci. USA, 89:6232-636 (1992)
- 145 Lavitrano et al., "Sperm Cells as vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice" Cell, 57:717-73 (1989)
- 146 Lee et al., "Complexes fromed by (pyrimidine)_n(purine)_n DNAs on lowering the pH are three-stranded" Nucl. Acids Res., 6:3073 (1979)
- 147 Li et al., "Targeted Mutation of the DNA Methytransferase Gene Results in Embryonic Lethality" Cell, 69:915 (1992)
- 148 Lo, Cecilia W., "Transformation by Iontophoretic Microinjection of DNA: Multiple Integration Without Tandem insertions" Mol. Cell Biol., 3:1803-1814 (1983)
- 149 Lonberg and Huszar, "Human Antibodies from trangenic Mice" Intern. Rev. Immunol. 13 65-93 (1995)
- 150 Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications" Nature 368 856-859 (1994)
- 151 Louvencourt et al., "Transformation of Kluyveromyces lactis by Killer Plasmid DNA", J. Bacteriol., 154(2): 737-1742 (1983)
- 152 Lucas et al., "High-Level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector" Nucl. Acids Res. 24(9):1774-1779 (1996)
- 153 Lutz-Freyermuth et al., "Quantitative determination that one of two potentail RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II OF U1 RNA" Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)
- 154 Mansour et al., "Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes" Nature, 336:348-352 (1988)
- 155 Mantei et al., "Rabbit -globin mRNA production in mouse L cells transformed with clone rabbit -globin chromosomal DNA" Nature, 281:40-46 (1979)
- 156 Marasco et al. "Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120- single-chain antibody, Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993)

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO GENENT 2827A2	APPLICATION NO. 09/759,056
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Pennica et al	
		FILING DATE January 11, 2001	GROUP 1645



OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- 157 Marks et al., "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage" J. Mol. Biol., 222:581 (1991)
- 158 Martin and Papahadjopoulos, "Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles" J. Biol. Chem., 257: 286-288 (1982)
- 159 Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K⁺ Channel Current" Science, 255:192-194 (1992)
- 160 Massey, "Catalytic antibodies catching on" Nature, 328:457-458 (1987)
- 161 Mather, Jennie P. "Establishment and Characterization of two Distinct Mouse Testicular Epithelial Cell Lines", Biol. Reprod., 23:243-251 (1980)
- 162 McGrew et al., "Direct regulation of the *Xenopus* engrailed-2 promoter by the Wnt signaling pathway, and a molecular screen for Wnt-responsive genes, confirm a role for Wnt signaling during neural patterning in *Xenopus*" Mech. Dev. 87:21-32 (1999)
- 163 Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of Tetrapeptide" J. Am. Chem. Soc., 85:2149-2154 (1963)
- 164 Milstein and Cuello, "Hybrid hybridomas and their use in immunohistochemistry" Nature, 305:537-539 (1983)
- 165 Mordenti, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" In Toxicokinetics and New Drug Development, Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 42-96
- 166 Morrison, Sherrie L., "Success in specification" Nature 368, 812-13 (1994)
- 167 Neuberger et al., "Recombinant antibodies possessing novel effector functions" Nature, 312:604-608 (1984)
- 168 Neuberger, Michael, "Generating high-avidity human Mabs in mice" Nature Biotechnology 14, 826 (1996)
- 169 Nygren, Hakan "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" J. Histochem. and Cytochem., 30:407 (1982)
- 170 Paborsky et al., "Mammalian cell transient expression of tissue factor for the production of antigen" Protein Engineering, 3(6):547-553 (1990)
- 171 Pain an Surolia "Preparation of Protein A-Peroxidase Monoconjugate using a Heterobifunctional Reagent, and its use in Enzyme Immunoassays" J. Immunol. Meth., 40:219 (1981)
- 172 Palladino et al. "Characterization of the Antitumor Activities of Human Tumor Necrosis Factor- and the Comparison with other Cytokines: Induction of Tumor-Specific Immunity", J. Immunol., 138:4023-4032 (1987)
- 173 Pennica et al., "WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors" Proc. Natl. Acad. Sci USA 95:14717-22 (1998)
- 174 Perry, M.C., Ed., Chemotherapy Source Book, Williams & Wilkins, Baltimore, MD (1992)
- 175 Polakis, Paul, "The oncogenic activation of -catenin" Curr. Opin. Genet. Dev. 9:15-21 (1999)
- 176 Presta, Leonard G., "Antibody engineering" Curr. Op. Struct. Biol., 2:593-596 (1992)
- 177 Ravdin and Channess, "The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review" Gene, 159:19-27 (1995)
- 178 Reichmann et al., "Reshaping human antibodies for therapy" Nature, 332:323-329 (1988)

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO GENENT.2827A2	APPLICATION NO. 09/759,056
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Pennica et al	
		FILING DATE January 11, 2001	GROUP 1645

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- 179 Rimm et al., "Frequent Nuclear/Cytoplasmic Localization of β -Catenin without Exon 3 Mutations in Malignant Adenoma" Am. J. Pathol. 154:325-9 (1999)
- 180 Rossi, John J., "Making ribozymes work in cells" Current Biology, 4:469-471 (1994)
- 181 Rubinfeld et al., "Association of the APC Gene Product with β -Catenin" Science 262:1731-1734 (1993)
- 182 Ruppert et al., "Cloning and expression of human TAD..250" a TBP-associated factor implicated in cell-cycle regulation" Nature, 362:175-179 (1993)
- 183 Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989)
- 184 Scholtissek and Grosse, "A cloning cartridge of ϕ 10 terminator" Nucleic Acids Res. 15:3185 (1987)
- 185 Schwab et al. "Amplification of Cellular Oncogenes: A Predictor of Clinical outcome in Human Cancer", Genes Chromosomes Cancer, 1:181-193 (1990)
- 186 Scopes, Robert K., Protein Purification: Principles and Practice, Springer-Verlag, New York (1982)
- 187 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" J. Exp. Med. 175:217-225 (1992)
- 188 Shopes, Bob, "A Genetically Engineered Human IgG Mutant With Enhanced Cytolytic Activity" J. Immunol., 148:2918:2922 (1992)
- 189 Slamon et al., "Human Breast Cancer" Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" Science, 235:177-182 (1987)
- 190 Small et al., "Analysis of a Transgenic Mouse Containing Simian Virus 40 and v-myc Sequences" Mol. Cell. Biol., 5:642-648 (1985)
- 191 Sojar and Bahl, et al., "A Chemical Method for the Deglycosylation of Proteins", Arch. Biochem. Biophys., 259:52-57(1987)
- 192 Somparyrac et al., "Efficient infection of monkey cells with DNA of simian virus 40" Proc. Natl. Acad. Sci., 12:7575 (1981)
- 193 Sreekrishna et al., "High level expression of heterologous proteins in methylotrophic yeast *Pichia pastoris*" J. Basic Microbiol., 28:265-278 (1988)
- 194 Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery", University of Kansas and Interx Research Corp., Lawrence, Kansas 66045
- 195 Stevenson et al. "A chimeric antibody with dual Fc regions (bisFaFc) prepared by manipulations at the IgG hinge", Anti-Cancer Drug Design, 3: 219-230 (1989)
- 196 Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969)
- 197 Stewart et al., "An STS-Based Radiation Hybrid Map of the Human Genome" Genome Research, 7:422-433 (1997)
- 198 Stinchcomb et al., "Isolation and characterization of yeast chromosomal replicator" Nature, 282:39 (1979)
- 199 Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" Methods in Enzymology, 121:210 (1986)
- 200 Taneja et al., "Reexpression of retinoic acid receptor (RAR) or overexpression of RAR or RAR in RAR -null F9 cells reveals a partial functional redundancy between the three RAR types" Proc. Natl. Acad. Sci. USA

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.2827A2	APPLICATION NO. 09/759,056
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Pennica et al	
		FILING DATE January 11, 2001	GROUP 1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Thimmappaya et al., "Adenovirus VAI RNA Is Required for Efficient Translation of Viral mRNAs at Late Times after infection" <u>Cell</u> , 31:543 (1982)
202	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> , 51:503 (1987)
203	Thomas, Patricia S., "Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> , 77:5201-5205 (1980)
204	Thompson et al., "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targeting in Embryonic Stem Cells" <u>Cell</u> , 56:313-321 (1989)
205	Thotakura and Bahl, "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> , 138:350 (1987)
206	Tilburn et al., "Transformation by Integration in <i>Aspergillus nidulans</i> ", <u>Gene</u> , 26:205-221 (1983)
207	Trautnecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells" <u>EMBO J.</u> , 10:3655-3659 (1991)
208	Tschumper et al., "Sequence of a yeast DNA fragment containing a chromosomal replicator and the TRP1 gene" <u>Gene</u> , 10:157 (1980)
209	Tsukamoto et al., "Expression of the int-1 Gene in Transgenic Mice Is Associated with Mammary Gland Hyperplasia and Adenocarcinomas in Male and Female Mice" <u>Cell</u> 55:619-625 (1988)
210	Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> , 77:4216 (1980)
211	Van der Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences" <u>BioTechniques</u> 6:958 (1988)
212	Van der Putten et al., "Efficient insertion of genes into the mouse germ line via retroviral vectors" <u>Proc. Natl. Acad. Sci. USA</u> , 82:6148-615 (1985)
213	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> , 130:946 (1977)
214	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> , 239:1534-1536 (1988)
215	Vitetta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents" <u>Science</u> , 238: 1098 (1987)
216	Wagner et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells" <u>Proc. Natl. Acad. Sci. USA</u> 87, 3410-3414 (1990)
217	Warzocha and Wotowiec, "Antisense strategy" biological utility and prospects in the treatment of hematological malignancies." <u>Leuk. Lymphoma</u> 24:267-281 (1997)
218	Wells et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites" <u>Gene</u> , 34:315 (1985)
219	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. R. Soc. London SerA</u> , 317:415-423 (1986)
220	Willert et al., "Wnt-induced dephosphorylation of Axin releases β -catenin from the Axin complex", <u>Genes Dev.</u> 13:1768-73 (1999)
221	Wilman, Derry E., "Prodrugs in Cancer Chemotherapy", <u>Biochemical Society Transactions</u> , 14:375-382, 615th Meeting, Belfast (1986)

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT 2827A2	APPLICATION NO. 09/759,056
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Pennica et al	
		FILING DATE January 11, 2001	GROUP 1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	222 Wright et al. " -Catenin mutation and expression analysis on ovarian cancer: Excon 3 mutations and nuclear translocation in 16% of endometrioid tumours" <u>Int. J. Cancer</u> 82:625-9 (1999)
	223 Wu et al., "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System" <u>J. Biol. Chem.</u> 262, 4429-4432 (1987)
	224 Yelton et al., "Transformation of <i>Aspergillus nidulans</i> by using trpC plasmid" <u>Proc. Natl. Acad. Sci. USA</u> , 81: 1470-1474 (1984)
	225 Zacharski, Leo R., "Basis for Selection of Anticoagulant Drugs for Therapeutic Trials in Human Malignancy" <u>Haemostasis</u> , 16:300-320 (1986)
	226 Zamecnik et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type IRII in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA" <u>Proc. Natl. Acad. Sci. USA</u> 83:4143-4146 (1986)
	227 Zapata et al., "Engineering linear F(ab') ₂ fragments for efficient production in <i>Escherichia coli</i> and enhanced antiproliferative activity" <u>Protein Eng.</u> , 8(10):1057-1062 (1995)
	228 Zola, Heddy, <u>Monoclonal Antibodies: A Manual of Techniques</u> , CRC Press, Inc. (1987) pp. 147-158
	229 Zupi et al. "Cloning in Vitro and in Vivo of Lewis Lung Carcinoma: Properties and Characteristics", <u>Br. J. Cancer</u> , 41:suppl. 4:309 (1980)

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT